{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:32:22Z","timestamp":1790037142776,"version":"4.0.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40263-015-0247-x","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T11:26:06Z","timestamp":1431429966000},"page":"397-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"29","author":[{"given":"Pablo","family":"Martinez-Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rodriguez-Blazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Forjaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Kurtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"issue":"7","key":"247_CR1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/00023210-200822070-00003","volume":"22","author":"DA Gallagher","year":"2008","unstructured":"Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson\u2019s disease. CNS Drugs. 2008;22(7):563\u201386.","journal-title":"CNS Drugs."},{"issue":"Suppl 1","key":"247_CR2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/PL00007733","volume":"245","author":"P Martinez-Martin","year":"1998","unstructured":"Martinez-Martin P. An introduction to the concept of \u201cquality of life in Parkinson\u2019s disease\u201d. J Neurol. 1998;245(Suppl 1):S2\u20136.","journal-title":"J Neurol."},{"key":"247_CR3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6947-13-6","volume":"13","author":"JA Sacrist\u00e1n","year":"2013","unstructured":"Sacrist\u00e1n JA. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Med Inform Decis Mak. 2013;13:6.","journal-title":"BMC Med Inform Decis Mak."},{"issue":"4","key":"247_CR4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/WCO.0b013e3283633741","volume":"26","author":"AHV Schapira","year":"2013","unstructured":"Schapira AHV. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol. 2013;26(4):395\u2013400.","journal-title":"Curr Opin Neurol."},{"issue":"13","key":"247_CR5","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/mds.24036","volume":"26","author":"JA Obeso","year":"2011","unstructured":"Obeso JA, Olanow W. Deep brain stimulation for Parkinson\u2019s disease: thinking about the long-term in the short-term. Mov Disord. 2011;26(13):2303\u20134.","journal-title":"Mov Disord."},{"issue":"3","key":"247_CR6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease. Mov Disord. 2011;26(3):399\u2013406.","journal-title":"Mov Disord."},{"issue":"11","key":"247_CR7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.parkreldis.2013.07.010","volume":"19","author":"B M\u00fcller","year":"2013","unstructured":"M\u00fcller B, Assmus J, Herlofson K, Larsen JP, Tysnes OB. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19(11):1027\u201332.","journal-title":"Parkinsonism Relat Disord."},{"key":"247_CR8","unstructured":"Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. London: European Medicines Agency; 2005. Report no.: EMEA\/CHMP\/EWP\/139391\/2004."},{"key":"247_CR9","unstructured":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Rockville: Food and Drug Administration; 2009."},{"issue":"13","key":"247_CR10","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/mds.23834","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, et al. Health-related quality-of-life scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord. 2011;26(13):2371\u201380.","journal-title":"Mov Disord."},{"issue":"Suppl 4","key":"247_CR11","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S1353-8020(09)70837-5","volume":"15","author":"P Martinez-Martin","year":"2009","unstructured":"Martinez-Martin P, Kurtis MM. Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. Parkinsonism Relat Disord. 2009;15(Suppl 4):S58\u201364.","journal-title":"Parkinsonism Relat Disord."},{"issue":"11","key":"247_CR12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0021-9681(86)90038-X","volume":"39","author":"RA Deyo","year":"1986","unstructured":"Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis. 1986;39(11):897\u2013906.","journal-title":"J Chronic Dis."},{"issue":"3 Suppl","key":"247_CR13","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1097\/00005650-198903001-00015","volume":"27","author":"LE Kazis","year":"1989","unstructured":"Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27(3 Suppl):S178\u201389.","journal-title":"Med Care."},{"issue":"2","key":"247_CR14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11136-004-0705-2","volume":"14","author":"KW Wyrwich","year":"2005","unstructured":"Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. Estimating clinically significant differences in quality of life outcomes. Qual Life Res. 2005;14(2):285\u201395.","journal-title":"Qual Life Res."},{"key":"247_CR15","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Academic Press; 1988.","edition":"2"},{"issue":"5","key":"247_CR16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0895-4356(03)00044-1","volume":"56","author":"RD Crosby","year":"2003","unstructured":"Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56(5):395\u2013407.","journal-title":"J Clin Epidemiol."},{"issue":"Suppl 4","key":"247_CR17","first-page":"IV43","volume":"252","author":"F Stocchi","year":"2005","unstructured":"Stocchi F. Optimising levodopa therapy for the management of Parkinson\u2019s disease. J Neurol. 2005;252(Suppl 4):IV43\u20138.","journal-title":"J Neurol."},{"issue":"8","key":"247_CR18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","volume":"21","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson\u2019s disease. CNS Drugs. 2007;21(8):677\u201392.","journal-title":"CNS Drugs."},{"issue":"2","key":"247_CR19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/ern.11.195","volume":"12","author":"RA Hauser","year":"2012","unstructured":"Hauser RA. IPX066: a novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother. 2012;12(2):133\u201340.","journal-title":"Expert Rev Neurother."},{"issue":"2","key":"247_CR20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol."},{"issue":"9949","key":"247_CR21","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"R Gray","year":"2014","unstructured":"PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196\u2013205.","journal-title":"Lancet."},{"issue":"Suppl. 3","key":"247_CR22","first-page":"171","volume":"5","author":"P Martinez-Martin","year":"1998","unstructured":"Martinez-Martin P, del Ser Quijano T, Aguilar M, Peto V, The QoL Study Group. Controlled-release levodopa-carbidopa (CRLC) treatment and quality of life of Parkinson\u2019s disease patients as measured by the PDQ-39. Eur J Neurol. 1998;5(Suppl. 3):171.","journal-title":"Eur J Neurol."},{"key":"247_CR23","first-page":"93","volume-title":"Quality of life in Parkinson\u2019s disease","author":"P Martinez-Martin","year":"1999","unstructured":"Martinez-Martin P, Koller WC. Quality of life benefit induced by controlled-release carbidopa\/levodopa formulation. In: Martinez-Martin P, Koller WC, editors. Quality of life in Parkinson\u2019s disease. Barcelona: Masson; 1999. p. 93\u2013105."},{"issue":"4","key":"247_CR24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","volume":"12","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson\u2019s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346\u201356.","journal-title":"Lancet Neurol."},{"issue":"2","key":"247_CR25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.parkreldis.2013.08.017","volume":"20","author":"R Pahwa","year":"2014","unstructured":"Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al. Randomized trial of IPX066, carbidopa\/levodopa extended release, in early Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(2):142\u20138.","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"247_CR26","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.1175","volume":"16","author":"W Koller","year":"2001","unstructured":"Koller W, Lees A, Doder M, Hely M, Tolcapone\/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson\u2019s disease patients with motor fluctuations. Mov Disord. 2001;16(5):858\u201366.","journal-title":"Mov Disord."},{"issue":"10","key":"247_CR27","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","volume":"61","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61(10):1563\u20138.","journal-title":"Arch Neurol."},{"issue":"11","key":"247_CR28","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/mds.21473","volume":"22","author":"G Deuschl","year":"2007","unstructured":"Deuschl G, Vaitkus A, Fox G-C, Roscher T, Schremmer D, Gordin A, et al. Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. Mov Disord. 2007;22(11):1550\u20135.","journal-title":"Mov Disord."},{"issue":"4","key":"247_CR29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00702-013-1114-x","volume":"121","author":"E Tolosa","year":"2014","unstructured":"Tolosa E, Hern\u00e1ndez B, Linazasoro G, L\u00f3pez-Lozano JJ, Mir P, Marey J, et al. Efficacy of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in patients with early Parkinson\u2019s disease experiencing mild wearing-off: a randomised, double-blind trial. J Neural Transm. 2014;121(4):357\u201366.","journal-title":"J Neural Transm."},{"issue":"1","key":"247_CR30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0404.2004.00363.x","volume":"111","author":"H Reichmann","year":"2005","unstructured":"Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K, et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111(1):21\u20138.","journal-title":"Acta Neurol Scand."},{"issue":"6","key":"247_CR31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0278-5846(03)00156-8","volume":"27","author":"O Gershanik","year":"2003","unstructured":"Gershanik O, Emre M, Bernhard G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson\u2019s disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):963\u201371.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"2","key":"247_CR32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000052104","volume":"45","author":"F Durif","year":"2001","unstructured":"Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I, F-01 Study Group. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson\u2019s disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol. 2001;45(2):111\u20138.","journal-title":"Eur Neurol."},{"issue":"8","key":"247_CR33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00702-004-0149-4","volume":"111","author":"M Onofrj","year":"2004","unstructured":"Onofrj M, Thomas A, Vingerhoets F, Martin W, Gim\u00e9nez-Rold\u00e1n S, Azulay J-P, et al. Combining entacapone with levodopa\/DDCI improves clinical status and quality of life in Parkinson\u2019s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm. 2004;111(8):1053\u201363.","journal-title":"J Neural Transm."},{"issue":"3","key":"247_CR34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1468-1331.2006.01635.x","volume":"14","author":"F Grandas","year":"2007","unstructured":"Grandas F, Hern\u00e1ndez B, PRACTICOMT Study Group. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson\u2019s disease patients: the effects of an early therapeutic intervention. Eur J Neurol. 2007;14(3):282\u20139.","journal-title":"Eur J Neurol."},{"issue":"1","key":"247_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.21060","volume":"22","author":"JG Nutt","year":"2007","unstructured":"Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord. 2007;22(1):1\u20139.","journal-title":"Mov Disord."},{"issue":"2","key":"247_CR36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01.wnf.0000240943.59617.4c","volume":"30","author":"Parkinson Study Group","year":"2007","unstructured":"Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol. 2007;30(2):72\u201385.","journal-title":"Clin Neuropharmacol."},{"issue":"4","key":"247_CR37","first-page":"707","volume":"4","author":"O Kano","year":"2008","unstructured":"Kano O, Ikeda K, Kiyozuka T, Iwamoto K, Ito H, Kawase Y, et al. Beneficial effect of pramipexole for motor function and depression in Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2008;4(4):707\u201310.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"6","key":"247_CR38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513\u201320.","journal-title":"Lancet Neurol."},{"issue":"1","key":"247_CR39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1185\/03007995.2012.752351","volume":"29","author":"F Viallet","year":"2013","unstructured":"Viallet F, Pitel S, Lancrenon S, Blin O. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson\u2019s disease. Curr Med Res Opin. 2013;29(1):23\u201331.","journal-title":"Curr Med Res Opin."},{"issue":"6","key":"247_CR40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11055-007-0050-3","volume":"37","author":"NV Fedorova","year":"2007","unstructured":"Fedorova NV, Chigir\u2019 IP. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson\u2019s disease. Neurosci Behav Physiol. 2007;37(6):539\u201346.","journal-title":"Neurosci Behav Physiol."},{"issue":"12","key":"247_CR41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0033-1351257","volume":"63","author":"M Takanashi","year":"2013","unstructured":"Takanashi M, Shimo Y, Hatano T, Oyama G, Hattori N. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson\u2019s disease: results from an open-label study. Drug Res. 2013;63(12):639\u201343.","journal-title":"Drug Res."},{"issue":"1","key":"247_CR42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/wnf.0b013e318067bcc4","volume":"31","author":"G Linazasoro","year":"2008","unstructured":"Linazasoro G, Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. Clin Neuropharmacol. 2008;31(1):19\u201324.","journal-title":"Clin Neuropharmacol."},{"issue":"Suppl 1","key":"247_CR43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000058049","volume":"46","author":"HK Baas","year":"2001","unstructured":"Baas HK, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson\u2019s disease. Eur Neurol. 2001;46(Suppl 1):18\u201323.","journal-title":"Eur Neurol."},{"issue":"1","key":"247_CR44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0404.2005.00514.x","volume":"113","author":"P Odin","year":"2006","unstructured":"Odin P, Oehlwein C, Storch A, Polzer U, Werner G, Renner R, et al. Efficacy and safety of high-dose cabergoline in Parkinson\u2019s disease. Acta Neurol Scand. 2006;113(1):18\u201324.","journal-title":"Acta Neurol Scand."},{"issue":"16","key":"247_CR45","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.21743","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al. Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22(16):2409\u201317.","journal-title":"Mov Disord."},{"issue":"14","key":"247_CR46","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108\u201315.","journal-title":"Neurology."},{"issue":"6","key":"247_CR47","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/ern.13.47","volume":"13","author":"BA Wright","year":"2013","unstructured":"Wright BA, Waters CH. Continuous dopaminergic delivery to minimize motor complications in Parkinson\u2019s disease. Expert Rev Neurother. 2013;13(6):719\u201329.","journal-title":"Expert Rev Neurother."},{"issue":"13","key":"247_CR48","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1517\/14656566.2011.604031","volume":"12","author":"L Ghys","year":"2011","unstructured":"Ghys L, Surmann E, Whitesides J, Boroojerdi B. Effect of rotigotine on sleep and quality of life in Parkinson\u2019s disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother. 2011;12(13):1985\u201398.","journal-title":"Expert Opin Pharmacother."},{"issue":"1","key":"247_CR49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90\u20139.","journal-title":"Mov Disord."},{"issue":"Pt 5","key":"247_CR50","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","volume":"136","author":"S Thobois","year":"2013","unstructured":"Thobois S, Lhomm\u00e9e E, Klinger H, Ardouin C, Schmitt E, Bichon A, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil. Brain. 2013;136(Pt 5):1568\u201377.","journal-title":"Brain."},{"key":"247_CR51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.phrs.2013.05.005","volume":"74","author":"S M\u00ednguez-M\u00ednguez","year":"2013","unstructured":"M\u00ednguez-M\u00ednguez S, Sol\u00eds-Garc\u00eda Del Pozo J, Jord\u00e1n J. Rasagiline in Parkinson\u2019s disease: a review based on meta-analysis of clinical data. Pharmacol Res. 2013;74:78\u201386.","journal-title":"Pharmacol Res."},{"issue":"5","key":"247_CR52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/mds.20764","volume":"21","author":"KM Biglan","year":"2006","unstructured":"Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, et al. Rasagiline improves quality of life in patients with early Parkinson\u2019s disease. Mov Disord. 2006;21(5):616\u201323.","journal-title":"Mov Disord."},{"issue":"12","key":"247_CR53","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002;59(12):1937\u201343.","journal-title":"Arch Neurol."},{"issue":"2","key":"247_CR54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241\u20138.","journal-title":"Arch Neurol."},{"issue":"9","key":"247_CR55","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/11316770-000000000-00000","volume":"26","author":"A Haycox","year":"2009","unstructured":"Haycox A, Armand C, Murteira S, Cochran J, Fran\u00e7ois C. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson\u2019s disease in the UK setting: an economic Markov model evaluation. Drugs Aging. 2009;26(9):791\u2013801.","journal-title":"Drugs Aging."},{"issue":"10","key":"247_CR56","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1055\/s-2008-1038249","volume":"76","author":"WH Jost","year":"2008","unstructured":"Jost WH, Klasser M, Reichmann H. Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment [in German]. Fortschr Neurol Psychiatr. 2008;76(10):594\u20139.","journal-title":"Fortschr Neurol Psychiatr."},{"issue":"9","key":"247_CR57","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1468-1331.2010.02986.x","volume":"17","author":"H Reichmann","year":"2010","unstructured":"Reichmann H, Jost WH. Efficacy and tolerability of rasagiline in daily clinical use\u2013a post-marketing observational study in patients with Parkinson\u2019s disease. Eur J Neurol. 2010;17(9):1164\u201371.","journal-title":"Eur J Neurol."},{"issue":"1","key":"247_CR58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/WNF.0b013e3181b7926f","volume":"33","author":"KE Lyons","year":"2010","unstructured":"Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, et al. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol. 2010;33(1):5\u201310.","journal-title":"Clin Neuropharmacol."},{"issue":"5","key":"247_CR59","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00702-012-0927-3","volume":"120","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Hoffmann JA, Dimpfel W, Oehlwein C. Switch from selegiline to rasagiline is beneficial in patients with Parkinson\u2019s disease. J Neural Transm. 2013;120(5):761\u20135.","journal-title":"J Neural Transm."},{"key":"247_CR60","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fnagi.2014.00180","volume":"6","author":"R Krishna","year":"2014","unstructured":"Krishna R, Ali M, Moustafa AA. Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson\u2019s disease. Front Aging Neurosci. 2014;6:180.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"247_CR61","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/17512433.2014.968555","volume":"7","author":"RM Kandadai","year":"2014","unstructured":"Kandadai RM, Jabeen SA, Kanikannan MA, Borgohain R. Safinamide for the treatment of Parkinson\u2019s disease. Expert Rev Clin Pharmacol. 2014;7(6):747\u201359.","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"2","key":"247_CR62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord. 2014;29(2):229\u201337.","journal-title":"Mov Disord."},{"issue":"10","key":"247_CR63","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord. 2014;29(10):1273\u201380.","journal-title":"Mov Disord."},{"issue":"4","key":"247_CR64","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord. 2015;30(4):510\u20136.","journal-title":"Mov Disord."},{"issue":"3","key":"247_CR65","first-page":"133","volume":"22","author":"B Casta\u00f1o","year":"2007","unstructured":"Casta\u00f1o B, Mateo D, Gim\u00e9nez-Rold\u00e1n S. Shifting to subcutaneous infusion of apomorphine in advanced Parkinson\u2019s disease patients on an out-patient basis: experience and recommendations [in Spanish]. Neurol Barc Spain. 2007;22(3):133\u20137.","journal-title":"Neurol Barc Spain."},{"issue":"5","key":"247_CR66","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0404.2008.01104.x","volume":"119","author":"D Nyholm","year":"2009","unstructured":"Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson\u2019s disease with symptom fluctuations. Acta Neurol Scand. 2009;119(5):345\u20138.","journal-title":"Acta Neurol Scand."},{"issue":"2","key":"247_CR67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-2011-11037","volume":"1","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Reddy P, Antonini A, Henriksen T, Katzenschlager R, Odin P, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson\u2019s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197\u2013203.","journal-title":"J Parkinsons Dis."},{"issue":"5","key":"247_CR68","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1185\/03007995.2011.560146","volume":"27","author":"HH Fernandez","year":"2011","unstructured":"Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson\u2019s disease. Curr Med Res Opin. 2011;27(5):907\u201319.","journal-title":"Curr Med Res Opin."},{"issue":"6","key":"247_CR69","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-0404.2008.01049.x","volume":"118","author":"D Isacson","year":"2008","unstructured":"Isacson D, Bingefors K, Kristiansen IS, Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand. 2008;118(6):379\u201386.","journal-title":"Acta Neurol Scand."},{"issue":"2","key":"247_CR70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/mds.23408","volume":"26","author":"AM Meppelink","year":"2011","unstructured":"Meppelink AM, Nyman R, van Laar T, Drent M, Prins T, Leenders KL. Transcutaneous port for continuous duodenal levodopa\/carbidopa administration in Parkinson\u2019s disease. Mov Disord. 2011;26(2):331\u20134.","journal-title":"Mov Disord."},{"issue":"1","key":"247_CR71","first-page":"79","volume":"16","author":"A Fasano","year":"2012","unstructured":"Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N. Intrajejunal levodopa infusion in advanced Parkinson\u2019s disease: long-term effects on motor and non-motor symptoms and impact on patient\u2019s and caregiver\u2019s quality of life. Eur Rev Med Pharmacol Sci. 2012;16(1):79\u201389.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"2","key":"247_CR72","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Nilsson Remahl AIM, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64(2):216\u201323.","journal-title":"Neurology."},{"issue":"9","key":"247_CR73","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1468-1331.2011.03630.x","volume":"19","author":"D Santos-Garc\u00eda","year":"2012","unstructured":"Santos-Garc\u00eda D, A\u00f1\u00f3n MJ, Fuster-Sanjurjo L, de la Fuente-Fern\u00e1ndez R. Duodenal levodopa\/carbidopa infusion therapy in patients with advanced Parkinson\u2019s disease leads to improvement in caregivers\u2019 stress and burden. Eur J Neurol. 2012;19(9):1261\u20135.","journal-title":"Eur J Neurol."},{"issue":"9","key":"247_CR74","first-page":"536","volume":"25","author":"D Santos-Garc\u00eda","year":"2010","unstructured":"Santos-Garc\u00eda D, Mac\u00edas M, Llaneza M, Fuster-Sanjurjo L, Echarri-Piudo A, Belmonte S, et al. Experience with continuous levodopa enteral infusion (Duodopa\u00ae) in patients with advanced Parkinson\u2019s disease in a secondary level hospital [in Spanish]. Neurol Barc Spain. 2010;25(9):536\u201343.","journal-title":"Neurol Barc Spain."},{"issue":"3","key":"247_CR75","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1600-0404.2011.01523.x","volume":"125","author":"D Santos-Garc\u00eda","year":"2012","unstructured":"Santos-Garc\u00eda D, Sanjurjo LF, Mac\u00edas M, Llaneza M, Carpintero P, de la Fuente-Fern\u00e1ndez R. Long-term exposure to duodenal levodopa\/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurol Scand. 2012;125(3):187\u201391.","journal-title":"Acta Neurol Scand."},{"issue":"1","key":"247_CR76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-012-6597-0","volume":"260","author":"M Zibetti","year":"2013","unstructured":"Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L, et al. Long-term duodenal levodopa infusion in Parkinson\u2019s disease: a 3-year motor and cognitive follow-up study. J Neurol. 2013;260(1):105\u201314.","journal-title":"J Neurol."},{"issue":"3","key":"247_CR77","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.parkreldis.2012.11.020","volume":"19","author":"HH Fernandez","year":"2013","unstructured":"Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease open-label study: interim results. Parkinsonism Relat Disord. 2013;19(3):339\u201345.","journal-title":"Parkinsonism Relat Disord."},{"issue":"1","key":"247_CR78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jclinepi.2009.03.011","volume":"63","author":"HCW Vet de","year":"2010","unstructured":"de Vet HCW, Terluin B, Knol DL, Roorda LD, Mokkink LB, Ostelo RWJG, et al. Three ways to quantify uncertainty in individually applied \u201cminimally important change\u201d values. J Clin Epidemiol. 2010;63(1):37\u201345.","journal-title":"J Clin Epidemiol."},{"issue":"2","key":"247_CR79","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1756285611431974","volume":"5","author":"P Martinez-Martin","year":"2012","unstructured":"Martinez-Martin P, Kurtis MM. Health-related quality of life as an outcome variable in Parkinson\u2019s disease. Ther Adv Neurol Disord. 2012;5(2):105\u201317.","journal-title":"Ther Adv Neurol Disord."},{"issue":"3","key":"247_CR80","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11136-012-0175-x","volume":"22","author":"KW Wyrwich","year":"2013","unstructured":"Wyrwich KW, Norquist JM, Lenderking WR, Acaster S, Industry Advisory Committee of International Society for Quality of Life Research (ISOQOL). Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res. 2013;22(3):475\u201383.","journal-title":"Qual Life Res."},{"issue":"3","key":"247_CR81","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/0272989X05276863","volume":"25","author":"B Barrett","year":"2005","unstructured":"Barrett B, Brown D, Mundt M, Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Mak. 2005;25(3):250\u201361.","journal-title":"Med Decis Mak."},{"issue":"1","key":"247_CR82","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cncr.22799","volume":"110","author":"J Ringash","year":"2007","unstructured":"Ringash J, O\u2019Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007;110(1):196\u2013202.","journal-title":"Cancer."},{"issue":"2","key":"247_CR83","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00019053-199915020-00003","volume":"15","author":"G Samsa","year":"1999","unstructured":"Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999;15(2):141\u201355.","journal-title":"Pharmacoeconomics."},{"issue":"3\u20134","key":"247_CR84","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000113714","volume":"5","author":"A Antonini","year":"2008","unstructured":"Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson\u2019s disease. Neurodegener Dis. 2008;5(3\u20134):244\u20136.","journal-title":"Neurodegener Dis."},{"issue":"10","key":"247_CR85","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, et al. Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10):1468\u201374.","journal-title":"Mov Disord."},{"issue":"3","key":"247_CR86","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.parkreldis.2009.07.015","volume":"16","author":"V Puente","year":"2010","unstructured":"Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson\u2019s disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord. 2010;16(3):218\u201321.","journal-title":"Parkinsonism Relat Disord."},{"issue":"6","key":"247_CR87","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1600-0404.2012.01689.x","volume":"126","author":"SE P\u00e5lhagen","year":"2012","unstructured":"P\u00e5lhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J, et al. Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand. 2012;126(6):e29\u201333.","journal-title":"Acta Neurol Scand."},{"key":"247_CR88","first-page":"362908","volume":"2013","author":"T Foltynie","year":"2013","unstructured":"Foltynie T, Magee C, James C, Webster GJM, Lees AJ, Limousin P. Impact of duodopa on quality of life in advanced Parkinson\u2019s disease: a UK case series. Parkinsons Dis. 2013;2013:362908.","journal-title":"Parkinsons Dis."},{"issue":"3","key":"247_CR89","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00415-013-7235-1","volume":"261","author":"MT C\u00e1ceres-Redondo","year":"2014","unstructured":"C\u00e1ceres-Redondo MT, Carrillo F, Lama MJ, Huertas-Fern\u00e1ndez I, Vargas-Gonz\u00e1lez L, Carballo M, et al. Long-term levodopa\/carbidopa intestinal gel in advanced Parkinson\u2019s disease. J Neurol. 2014;261(3):561\u20139.","journal-title":"J Neurol."},{"issue":"6","key":"247_CR90","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00702-013-1153-3","volume":"121","author":"M Sensi","year":"2014","unstructured":"Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D, Capone JG, et al. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J Neural Transm. 2014;121(6):633\u201342.","journal-title":"J Neural Transm."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0247-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-015-0247-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0247-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T03:12:15Z","timestamp":1599016335000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-015-0247-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1007\/s40263-015-0247-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}